Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Neoantigen Peptide Vaccines for Solid Tumors
NCT07002203Phase 2Recruiting
- Sponsor
- Seqker Biosciences
- Start
- Mar 2024
- Primary completion
- Aug 2027
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of personalized neoantigen peptide vaccine in solid tumor, sponsored by Seqker Biosciences. Started Mar 2024; status: recruiting.
02
Drugs
personalized neoantigen peptide vaccine
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07002203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07002203.